Breast Cancer Medical Oncologists in Melbourne
Breast cancer is not a single disease. Treatment is guided by the stage of the cancer and by biological features such as hormone receptor status, HER2 status and, in selected situations, inherited or tumour genetic changes. Surgery and radiotherapy remain important local treatments, while a medical oncologist advises on systemic treatments that travel through the body, including chemotherapy, endocrine therapy, HER2-targeted treatment and newer targeted or immune therapies.
Our oncologists work alongside breast surgeons, radiation oncologists, radiologists, pathologists and other members of the multidisciplinary team. The aim is to explain what the pathology means, estimate the likely benefit of different systemic treatments and develop a plan that reflects both the cancer biology and the patient’s priorities.
For early breast cancer, the medical oncologist is often involved after surgery, although some patients benefit from systemic treatment before surgery. Pathology from the biopsy or operation provides information about tumour size, lymph nodes, grade, hormone receptors and HER2. Genomic assays may be considered in selected hormone receptor-positive cancers when the benefit of chemotherapy is uncertain. Systemic therapy is used to reduce the risk of cancer returning and may include endocrine therapy, chemotherapy, HER2-directed treatment or combinations depending on the subtype and individual recurrence risk.
Many breast cancers express oestrogen and/or progesterone receptors. Endocrine treatment reduces the ability of hormones to stimulate these cancer cells and may include tamoxifen or aromatase inhibitors, with ovarian suppression in selected premenopausal patients. Treatment commonly continues for several years. Decisions take into account recurrence risk, menopausal status, bone health and side effects such as hot flushes, joint symptoms or changes in sexual health. In advanced disease, endocrine therapy is frequently combined with targeted medicines such as CDK4/6 inhibitors.
HER2-positive breast cancers have increased HER2 signalling and can respond to therapies that specifically target this pathway. Treatment may combine chemotherapy with HER2-directed medicines in early disease, while several targeted options are available for advanced disease. Heart function is usually monitored with some HER2-directed treatments. The exact sequence depends on disease stage, response to previous treatment and whether the cancer has spread to particular sites such as the brain.
Triple-negative breast cancer does not express oestrogen receptors, progesterone receptors or HER2. Chemotherapy is an important treatment and immunotherapy is used in selected early and advanced cancers according to clinical and biomarker criteria. Treatment planning is increasingly individualised according to stage, response to pre-operative treatment and tumour biology.
Metastatic breast cancer has spread beyond the breast and regional lymph nodes to another part of the body. It is usually treated as a long-term systemic illness rather than with one curative operation. Treatment aims to control cancer, relieve symptoms and preserve quality of life for as long as possible. The available options depend strongly on tumour subtype and previous treatments and can include endocrine therapy, targeted medicines, chemotherapy, antibody-drug conjugates and immunotherapy. Palliative care can be involved early for symptom support alongside active anti-cancer treatment.
Medical oncology review usually includes the pathology report, imaging, operative findings if relevant and blood tests. Additional tumour or germline genetic testing may be discussed when it can influence treatment or have implications for relatives. In metastatic disease, a biopsy of a new site is sometimes recommended because receptor status can differ from the original breast cancer.
A major part of the consultation is putting absolute treatment benefits and risks into context. Two people with the same broad label of “breast cancer” can have quite different recommendations because of tumour size, lymph nodes, receptor status, age, other illnesses and personal preferences.
Systemic cancer therapies may be delivered through the day oncology service at Northern Private Hospital or Northern Health when clinically appropriate. The treating oncologist monitors blood counts, organ function, treatment response and side effects, and adjusts dosing or supportive medicines when required. Where appropriate, referrals to exercise physiology, lymphoedema or other supportive services can also be coordinated as part of the broader plan.
Northern Blood & Cancer Care has particular breast oncology expertise, supported by multidisciplinary breast cancer care and active clinical-trial involvement across major Melbourne cancer services. This clinical and research experience supports access to contemporary treatment discussions close to Melbourne’s northern suburbs.
Northern Blood & Cancer Care brings together Melbourne specialists with complementary clinical, hospital and research appointments. The clinicians most closely associated with this service include:
Northern Blood & Cancer Care offers substantial breast oncology experience, supported by multidisciplinary breast cancer care and clinical-trial involvement. This combination of clinical and research expertise supports personalised discussion of contemporary systemic treatment options.
Northern Blood & Cancer Care brings together a highly experienced team of haematologists, medical oncologists and specialist physicians, with consultations available at Northern Private Hospital in Epping.
Contact our team to arrange an appointment or discuss a referral.
